| Angela Hardin, PTA | |
|
1787 Allendale Fairfax Hwy, Fairfax, SC 29827-9133 | |
| (803) 632-3311 | |
| Not Available |
| Full Name | Angela Hardin |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 1787 Allendale Fairfax Hwy, Fairfax, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811479660 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 2256 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Angela Hardin, PTA 3029 Old Highway 52, Moncks Corner, SC 29461-6847 Ph: (843) 442-0892 | Angela Hardin, PTA 1787 Allendale Fairfax Hwy, Fairfax, SC 29827-9133 Ph: (803) 632-3311 |
News Archive
A meta-analysis of four randomized Phase III placebo-controlled trials confirms that the injectable drug Efalizumab, a humanized therapeutic antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis, had an acceptable safety and efficacy profile in the treatment of psoriasis in heavy patients, researchers at Mount Sinai School of Medicine announced today.
Aiming to reduce cancer risk, improve the understanding of cancer outcomes, and promote cancer health equity in our most vulnerable populations at the community level, the Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey have recruited Anita Y. Kinney, PhD, as Director of the Center of Cancer Health Disparities at the Rutgers School of Public Health and Associate Director of Cancer Health Equity and Engagement at Rutgers Cancer Institute.
A new study at the University of Leicester is examining a sequence of DNA- known as telomeres - that varies in length between individual.
The biological clock is present in almost all cells of an organism. As more and more evidence emerges that clocks in certain organs could be out of sync, there is a need to investigate and reset these clocks locally.
Oncolytics Biotech Inc. announced today that following submission to the U.S. Food and Drug Administration for review, the Company is initiating a U.S. Phase I study of REOLYSIN(R) in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer.
› Verified 9 days ago